POTOMAC, Md., April 16, 2024--IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two.
POTOMAC, Md., April 09, 2024--IGC Pharma Adds Advisor in Artificial Intelligence
POTOMAC, Md., March 26, 2024--IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock